BACKGROUND: Strategies to improve I131 uptake in thyroid carcinoma include levothyroxine (LT4) withdrawal or thyrotropin (TSH) administration along with a low-iodine diet. We report five patients with papillary or follicular thyroid carcinoma who developed symptomatic hyponatremia during LT4 withdrawal and low-iodine diet. RESULTS: Four patients had pulmonary and/or brain metastases. All had restricted iodine intakes during LT4 withdrawal. Presenting complaints included weakness, dizziness, fainting spells, lethargy, and/or nausea. Baseline serum sodium levels while on LT4 suppression were normal. During presentation all were hypothyroid and serum sodium ranged from 110 to 121 mmol/L (normal 135-148). Despite hyponatremia, the plasma renin activity and serum aldosterone levels were suppressed, indicating volume expansion. The hyponatremia responded to fluid restriction and normalized after LT4 replacement. Low sodium intake, inappropriate antidiuretic hormone secretion syndrome (SIADH)-like disorder secondary to hypothyroidism and/or lung or cerebral metastases may have contributed to hyponatremia. CONCLUSIONS: The development of hyponatremia during LT4 withdrawal and low-iodine diet in otherwise healthy patients with thyroid carcinoma is extremely rare. However, elderly patients with metastatic thyroid carcinoma need observation during LT4 withdrawal combined with a low-iodine diet and should receive instruction to take iodine-free sodium chloride. Free water restriction may be necessary in some patients.
BACKGROUND: Strategies to improve I131 uptake in thyroid carcinoma include levothyroxine (LT4) withdrawal or thyrotropin (TSH) administration along with a low-iodine diet. We report five patients with papillary or follicular thyroid carcinoma who developed symptomatic hyponatremia during LT4 withdrawal and low-iodine diet. RESULTS: Four patients had pulmonary and/or brain metastases. All had restricted iodine intakes during LT4 withdrawal. Presenting complaints included weakness, dizziness, fainting spells, lethargy, and/or nausea. Baseline serum sodium levels while on LT4 suppression were normal. During presentation all were hypothyroid and serum sodium ranged from 110 to 121 mmol/L (normal 135-148). Despite hyponatremia, the plasma renin activity and serum aldosterone levels were suppressed, indicating volume expansion. The hyponatremia responded to fluid restriction and normalized after LT4 replacement. Low sodium intake, inappropriate antidiuretic hormone secretion syndrome (SIADH)-like disorder secondary to hypothyroidism and/or lung or cerebral metastases may have contributed to hyponatremia. CONCLUSIONS: The development of hyponatremia during LT4 withdrawal and low-iodine diet in otherwise healthy patients with thyroid carcinoma is extremely rare. However, elderly patients with metastatic thyroid carcinoma need observation during LT4 withdrawal combined with a low-iodine diet and should receive instruction to take iodine-free sodium chloride. Free water restriction may be necessary in some patients.
Authors: Anna M Sawka; Irada Ibrahim-Zada; Philip Galacgac; Richard W Tsang; James D Brierley; Shereen Ezzat; David P Goldstein Journal: Thyroid Date: 2010-10 Impact factor: 6.568
Authors: Fabian Beier; Lukas Moleda; Viktoria Guralnik; Philipp Hahn; Katharina Schardt; Reinhard Andreesen; Jürgen Schölmerich; Andreas Schäffler Journal: J Med Case Rep Date: 2010-04-21
Authors: Jeong-Ah Moon; Chang-Hee Yoo; Mi Hwa Kim; Song Mi Lee; Young Ja Oh; Young Hoon Ryu; Yong Sang Lee; Hang Seok Chang; Cheong Soo Park; Kyung-Eun Lee Journal: Clin Nutr Res Date: 2012-07-26
Authors: Hyo Jin Jo; Yong Hyun Kim; Dong Hyun Shin; Mi Jeoung Kim; Sang Jin Lee; Dong Ok Jeon; Sung Gyu Im; Sun Kyung Jang; Jin Young Choi Journal: Endocrinol Metab (Seoul) Date: 2014-03-14
Authors: Jung Eun Lee; Seung Kyu Kim; Kyung Hwa Han; Mi Ok Cho; Gi Young Yun; Ki Hyun Kim; Hoon Young Choi; Young Hoon Ryu; Sung Kyu Ha; Hyeong Cheon Park Journal: PLoS One Date: 2014-08-29 Impact factor: 3.240